ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2155 • ACR Convergence 2022

    Sclerodermoid Reaction Following Immune Checkpoint Inhibitor Therapy: A Case Series from MD Anderson Cancer Center

    Julia Chernis1 and Maryam Buni2, 1McGovern Medical School at the UTHSC Houston, Houston, TX, 2MD Anderson Cancer Center, Bellaire, TX

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have proven to be efficacious in the treatment of multiple malignancies.[1] they are associated immunologic activation has been implicated in…
  • Abstract Number: 2159 • ACR Convergence 2022

    Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort – Associations and Effect of Treatment

    Alannah Quinlivan1, Dennis Neuen2, Dylan Hansen3, Wendy Stevens3, Laura Ross4, Nava Ferdowsi3, Susanna Proudman5, Jenny Walker6, Jo Sahhar7, Gene-Siew Ngian8, Diane Apostolopoulos9, Lauren Host10, Gabor Major11, Kathleen Morrisroe3 and Mandana Nikpour12, 1St Vincent's Hospital Melbourne and the University of Melbourne, Melbourne, Australia, 2Liverpool Hospital, Sydney, Australia, 3St Vincent's Hospital Melbourne, Melbourne, Australia, 4The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, 5University of Adelaide, Medindie, Australia, 6Flinders Medical Centre, Flinders University, Daw Park, Australia, 7Monash Health, Melbourne, Australia, 8Melbourne Health, Northcote, Australia, 9Monash University, Melbourne, Australia, 10Fiona Stanley Hospital, London, United Kingdom, 11Hunter New England Health Service, Rankin Park - Newcastle, New South Wales, Australia, 12The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: To investigate the association between gastroesophageal reflux disease (GORD) and interstitial lung disease (ILD) and determine the effect of GORD treatment on survival in…
  • Abstract Number: 2160 • ACR Convergence 2022

    The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients

    Henriette Didriksen1, Øyvind Molberg2, Adi Mehta3, Suzana Jordan4, Håvard Fretheim3, Einar Gude3, Thor Ueland3, Cathrine Brunborg3, Vyacheslav Palchevskiy5, Torhild Garen3, Øyvind Midtvedt3, Arne Andreassen3, Fridtjof Lund-Johansen3, Oliver Distler4, John Belperio5 and Anna-Maria Hoffmann-Vold3, 1Oslo University Hospital, Moss, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 3Oslo University Hospital, Oslo, Norway, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 5University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Chemokines appear to be important for the pathogenesis of autoimmune diseases. Humans may generate antibodies targeting chemokines leading to inhibition of signaling and driving…
  • Abstract Number: 2154 • ACR Convergence 2022

    An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin

    Elizabeth Bundschuh1, Rebecca Fine2, Miruna Carnaru3, Sanchit Kumar4, Francis Perry Wilson2, Alyssa Williams1, Shannon Teaw4, Ian Odell4 and Monique Hinchcliff5, 1Yale University, New Haven, CT, 2Yale School of Medicine, New Haven, CT, 3Hartford Healthcare Medical Group, Rocky Hill, CT, 4Yale University School of Medicine, New Haven, CT, 5Yale School of Medicine, Westport, CT

    Background/Purpose: Receptor tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) and others including PDGFRs, FGFRs, and VEGFRs are implicated in systemic sclerosis (SSc)…
  • Abstract Number: 2038 • ACR Convergence 2022

    Single Cell RNA Sequencing Points to a Role for Fibroblasts Early in Salivary Gland Dysfunction in Primary Sjögren’s Syndrome

    Sarah Pringle1, Fred Spijkervet1, Arjan Vissink2, Hendrika Bootsma1 and Frans Kroese1, 1University Medical Center Groningen, Groningen, Netherlands, 2UMCG, Leek, Netherlands

    Background/Purpose: Salivary gland (SG) dysfunction is commonly associated with the autoimmune disease primary Sjögren's syndrome (pSS). Whilst the more advanced stages of the disease are…
  • Abstract Number: 2101 • ACR Convergence 2022

    Outcomes of Autoimmune Hemolytic Anemia in Patients with Systemic Lupus Erythematosus: A Nationwide Inpatient Sample Study

    Ekrem Turk, Vaishali Deenadayalan, Khaldun Obeidat and Pierre Rodriguez, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL

    Background/Purpose: Autoimmune Hemolytic Anemia (AIHA) is one of the manifestations of Systemic lupus erythematosus (SLE), an autoimmune connective tissue disease. AIHA may be present in…
  • Abstract Number: 2146 • ACR Convergence 2022

    Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years

    Philip J Mease1, Rodrigo Luppino Assad2, Shigeyoshi Tsuji3, Pascal Richette4, Arathi Setty5, Erin McDearmon-Blondell6, Tianming Gao5, Sandra Ciecinski6 and Filip Van den bosch7, 1Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 2Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, 3Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, 4Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, 5AbbVie, Inc., North Chicago, IL, 6AbbVie, Inc., Mettawa, IL, 7Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium

    Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
  • Abstract Number: 2031 • ACR Convergence 2022

    Efficacy and Safety of Telitacicept in Primary Sjögren’s Syndrome: A Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

    Dong Xu1, Shangzhu Zhang1, Cibo Huang2, Chenghui Huang3, Li Qin4, Xiaomei Li5, Meiqing Chen6, Xiumei Liu7, Yi Liu8, Zhijun Li9, Jiankang Hu10, Chunde Bao11, wei Wei12, Jing Tian13, Xinwang Duan14, Jianmin Fang15 and Xiaofeng Zeng16, 1Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Beijing Hospital, Beijing, China, 3The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 4Huzhou Third Municipal Hospital, Huzhou, China, 5Anhui Provincial Hospital, Hefei, China, 6The First Affiliated Hospital of Xiamen University, Xiamen, China, 7The First Hospital of Shanxi Medical University, Taiyuan, China, 8West China Hospital of Sichuan University, Chengdu, China, 9The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, 10Jiangxi Pingxiang People’s Hospital, Shanghai, China, 11Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, 12Tianjin Medical University General Hospital, Tianjin, China, 13Second Xiangya Hospital of Central South University, Changsha, China, 14The Second Affiliated Hospital of Nanchang University, Nanchang, China, 15Shanghai Tongji Hospital, Shanghai, China, 16Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: To evaluate the efficacy and safety of telitacicept in adult patients with primary Sjögren’s syndrome (pSS) in a phase II randomized double-blind placebo-controlled trial.Methods:…
  • Abstract Number: 1576 • ACR Convergence 2022

    Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis

    Umar Ghaffar1, Hannah Langenfeld2, Cynthia Crowson3, Tanaz Kermani4, Michelle Burke1, Boyd Viers1, Aaron Potretzke1, Haraldur Bjarnason1, Kenneth J. Warrington1 and Matthew J. Koster1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic, Eyota, MN, 4University of California Los Angeles, West Hills, CA

    Background/Purpose: To evaluate the presentation features and outcomes of patients with chronic abdominal periaortitis in a large referral cohort. Methods: Using a proprietary medical text…
  • Abstract Number: 2133 • ACR Convergence 2022

    Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis

    Oliver FitzGerald1, Dafna Gladman2, Philip J Mease3, Christopher Ritchlin4, Josef Smolen5, Lu Gao6, Sarah Hu6, Miroslawa Nowak6, Subhashis Banerjee6 and Ian M. Catlett6, 1Conway Institute, University College Dublin, Dublin, Ireland, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 4Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 5Medical University of Vienna, Vienna, Austria, 6Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Deucravacitinib (DEUC) is a novel, oral, selective TYK2 inhibitor with a unique allosteric mechanism of action that has demonstrated efficacy in patients with psoriasis1…
  • Abstract Number: 2157 • ACR Convergence 2022

    Evaluation of Functional Disability over Time in the Leiden Systemic Sclerosis (CCISS) Cohort

    Sophie Liem1, Saad Ahmed2, Tom Huizinga3, Thea Vliet Vlieland4, Sytske Anne Bergstra1 and Jeska de Vries-Bouwstra3, 1LUMC, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Leiden University Medical Center, Leiden, Netherlands, 4Department of Orthopaedics, Rehabilitation and Physical Therapy, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Functional disability in patients with systemic sclerosis (SSc) greatly influences quality of life. In SSc, the goal of treatment is to decrease disease burden…
  • Abstract Number: 2142 • ACR Convergence 2022

    Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial

    William Tillett1, Laura Coates2, Mohamed Sharaf3, Marlies Neuhold4, Elke Theander5, Paul Bergmans6, May Shawi7, Michelle Perate8, Christine Contré9 and Philip Helliwell10, 1Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, 6Formerly at Janssen, Breda, Netherlands, 7Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 10Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Accurate assessment of psoriatic arthritis (PsA) disease activity in clinical practice requires a feasible, continuous, multidimensional composite instrument to assess key domains of this…
  • Abstract Number: 2110 • ACR Convergence 2022

    Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population

    Laure Gossec1, Mohamed Sharaf2, Elke Theander3, Marlies Neuhold4, Paul Bergmans5, May Shawi6, Michelle Perate7, Christine Contré8 and Laura Coates9, 1Sorbonne Université, Paris, France, 2Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, 3Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, 4Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, 5Formerly at Janssen, Breda, Netherlands, 6Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, 7Janssen Scientific Affairs, LLC, Horsham, PA, 8Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, 9Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

    Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…
  • Abstract Number: 2049 • ACR Convergence 2022

    ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive

    Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Phoung Phoung Diep1, Karoline Lerang2, Birgir Gudbransson1, Helena Andersson1, Øyvind Midtvedt1, Torhild Garen1, Michael Durheim1, Trond Mogens Aaløkken1, Øyvind Palm1 and Øyvind Molberg2, 1Oslo University Hospital, Oslo, Norway, 2Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Interstitial lung disease (ILD) in primary Sjögren's syndrome (pSS) has been reported to be present in 10-15% of patients, but ILD progression in pSS-ILD…
  • Abstract Number: 2040 • ACR Convergence 2022

    Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study

    Astrid Rasmussen1, R. Hal Scofield2, Kiely Grundahl1, Lida Radfar2, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…
  • « Previous Page
  • 1
  • …
  • 426
  • 427
  • 428
  • 429
  • 430
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology